risedronic acid has been researched along with Fibrous Dysplasia of Bone in 1 studies
Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.
Fibrous Dysplasia of Bone: A disease of bone marked by thinning of the cortex by fibrous tissue containing bony spicules, producing pain, disability, and gradually increasing deformity. Only one bone may be involved (FIBROUS DYSPLASIA, MONOSTOTIC) or several (FIBROUS DYSPLASIA, POLYOSTOTIC).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chapurlat, R | 1 |
1 other study available for risedronic acid and Fibrous Dysplasia of Bone
| Article | Year |
|---|---|
Current pharmacological treatment for fibrous dysplasia and perspectives for the future.
Topics: Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Fibrous Dysplasia of Bone; Humans; Randomi | 2005 |